OncoMatch/Clinical Trials/NCT07030907
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Is NCT07030907 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies OPB-101 for ovarian cancer recurrent.
Treatment: OPB-101 — The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 germline or somatic mutation
Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
Allowed: BRCA2 germline or somatic mutation
Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Received at least 2 prior lines of systemic chemotherapy including a platinum-based chemotherapy.
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study intervention
Prior radiotherapy within 2 weeks of start of study intervention.
Cannot have received: chemotherapy
Exception: within the previous 3 weeks
Received chemotherapy within the previous 3 weeks.
Cannot have received: CAR-T cell therapy
Received prior CAR T cell therapy.
Cannot have received: mesothelin targeted therapy
Received prior mesothelin targeted therapy.
Cannot have received: investigational agents or tumor vaccines
Received investigational agents or tumor vaccines.
Lab requirements
Liver function
alkaline phosphatase ≤ 2.5 x uln
Cardiac function
lvef ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Karmanos Cancer Institute · Detroit, Michigan
- University of Minnesota · Minneapolis, Minnesota
- Roswell Park · Buffalo, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify